Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 291,652 shares.
Mateon Therapeutics Stock Up 7.2 %
The firm’s fifty day moving average is $0.04 and its two-hundred day moving average is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Micron Stock Under $100: Seize the AI-Driven Upside
- What Do S&P 500 Stocks Tell Investors About the Market?
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- What is Insider Trading? What You Can Learn from Insider Trading
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
